Originally published 2020-06-28.

In June 2020, a large British trial produced the first clear proof that a medicine could save lives from COVID-19. The RECOVERY trial, run by the University of Oxford in NHS hospitals, found that dexamethasone, an old and inexpensive steroid, reduced deaths by about a third among patients on ventilators and by about a fifth among patients who needed oxygen. It did not help people with milder illness who did not need breathing support.
This is what the trial found, why the result mattered so much, how dexamethasone works, and why it was never a drug to take at home.
What the RECOVERY trial found
RECOVERY (Randomised Evaluation of COVID-19 Therapy) was set up in March 2020 to test several possible treatments quickly in hospital patients. By June it had enrolled more than 11,500 people in over 175 NHS hospitals.
For the dexamethasone part of the study, 2,104 patients were randomly assigned to receive 6 mg of the drug once a day for ten days, by mouth or by injection, and 4,321 received usual care alone. After 28 days the researchers compared deaths in the two groups:
- Patients on a ventilator: deaths fell by about 35 per cent, a rate ratio of 0.65. Without the drug, about 41 per cent of these patients died.
- Patients on oxygen but not ventilated: deaths fell by about 20 per cent. About 25 per cent of these patients died with usual care.
- Patients needing no breathing support: there was no benefit, and the trend was slightly in the wrong direction.
Put another way, the researchers estimated that treating about eight ventilated patients, or about 25 patients on oxygen, would prevent one death. Joint chief investigator Peter Horby summed it up: "The survival benefit is clear and large."
Why the result was a turning point
Until then, doctors had only supportive care to offer seriously ill COVID-19 patients: oxygen, ventilation and careful nursing. Several heavily promoted drugs had either not been properly tested or were failing in trials. RECOVERY itself reported in June 2020 that hydroxychloroquine and the HIV drug combination lopinavir-ritonavir did not help hospital patients.
England's Chief Medical Officer, Professor Chris Whitty, welcomed the dexamethasone finding on the day it was announced:
This is the most important trial result for COVID-19 so far. Significiant reduction in mortality in those requiring oxygen or ventilation from a widely available, safe and well known drug. Many thanks to those who took part and made it happen. It will save lives around the world. https://t.co/zRIaHulHOe
— Professor Chris Whitty (@CMO_England) June 16, 2020
The UK government's chief scientific adviser, Sir Patrick Vallance, described it as "a ground-breaking development in our fight against the disease", and the drug was approved for use in NHS hospitals for suitable patients almost immediately.
How a cheap steroid helps the sickest patients
Dexamethasone is a corticosteroid that has been used since the early 1960s for conditions such as severe asthma, arthritis flare-ups, allergic reactions and some cancers. It does not attack the coronavirus. Instead, it calms the immune system.
In severe COVID-19, much of the lung damage is caused not only by the virus but by the body's own overactive inflammatory response. Dampening that response in patients who are already struggling to breathe can help the lungs recover. In patients with mild illness, by contrast, the immune system is still needed to fight the virus, which is one reason the drug showed no benefit, and possibly some risk, in that group.
The other major advantage was practical. Dexamethasone is off-patent, made by many manufacturers and already stocked in hospitals around the world. A course was reported to cost only a few pounds, which meant poorer countries could use it straight away. A later estimate suggested it could save around 650,000 lives worldwide over its first six months of use.
A patient's story
Alex Guerrero, a 45-year-old Londoner, spent two weeks in intensive care in Leicester. While he was critically ill, his wife agreed that he could join the trial, and his medical notes later showed he had received dexamethasone. He recovered, and told his local paper that he was grateful for her decision, while being honest about the uncertainty: "I will never know whether it was the drug that saved my life."
That caution is exactly right. A trial tells us how a treatment works on average across thousands of people. It cannot tell any single survivor what made the difference for them, which is why randomised trials, rather than individual stories, are needed to judge treatments.
Myths and misunderstandings
"Dexamethasone cures COVID-19." It does not cure the infection. It reduces the risk of death in patients sick enough to need oxygen or a ventilator.
"It is completely safe, so anyone can take it." It is well understood, but steroids can raise blood sugar, increase infection risk and cause other side effects. The World Health Organization stressed that it should be used only for severe or critical cases under close medical supervision, and that there was no evidence it helped mild illness or worked as prevention.
"It works for every patient." The benefit was limited to patients receiving breathing support. That is why it should never be bought or taken at home to treat or prevent COVID-19. Anyone with symptoms should talk to a doctor.
What happened next
The preliminary results were posted as a preprint on 22 June 2020 and published in The New England Journal of Medicine in July 2020. A WHO-linked review of other steroid trials in September 2020 confirmed the benefit, and corticosteroids became a standard part of hospital care for severe COVID-19 worldwide.
RECOVERY went on to enrol more than 40,000 patients and to test many other treatments. In 2021 it showed that tocilizumab, an anti-inflammatory antibody, also reduced deaths in hospitalised patients with severe disease. The first COVID-19 vaccines were approved at the end of 2020, changing the course of the pandemic. Dexamethasone remains one of the clearest examples of how a well-designed trial can turn an old, cheap medicine into a life-saving treatment within weeks.
Sources: University of Oxford: Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19; Wikipedia: RECOVERY Trial; ITV News; Leicester Mercury; Professor Chris Whitty (@CMO_England) on X, 16 June 2020.

COMMENTS